• DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
  • DNDi_Logo_No-Tagline_Full Colour
  • Our work
    • Diseases
      • Sleeping sickness
      • Visceral leishmaniasis
      • Cutaneous leishmaniasis
      • Chagas disease
      • Filaria: river blindness
      • Mycetoma
      • Paediatric HIV
      • Cryptococcal meningitis
      • Hepatitis C
      • Dengue
      • Pandemic preparedness
      • Antimicrobial resistance
    • Research & development
      • R&D portfolio & list of projects
      • Drug discovery
      • Translational research
      • Clinical trials
      • Registration & access
      • Treatments delivered
    • Advocacy
      • Open and collaborative R&D
      • Transparency of R&D costs
      • Pro-access policies and IP
      • Children’s health
      • Gender equity
      • Climate change
      • AI and new technologies
  • Networks & partners
    • Partnerships
      • Our partners
      • Partnering with us
    • Global networks
      • Chagas Platform
      • Dengue Alliance
      • HAT Platform
      • LEAP Platform
      • redeLEISH Network
    • DNDi worldwide
      • DNDi Switzerland
      • DNDi DRC
      • DNDi Eastern Africa
      • DNDi Japan
      • DNDi Latin America
      • DNDi North America
      • DNDi South Asia
      • DNDi South-East Asia
  • News & resources
    • News & stories
      • News
      • Stories
      • Statements
      • Viewpoints
      • Social media
      • eNews Newsletter
    • Press
      • Press releases
      • In the media
      • Podcasts, radio & TV
      • Media workshops
    • Resources
      • Scientific articles
      • Our publications
      • Videos
    • Events
  • About us
    • About
      • Who we are
      • How we work
      • Our strategy
      • Our donors
      • Annual reports
      • Our prizes and awards
      • Our story: 20 years of DNDi
    • Our people
      • Our leadership
      • Our governance
      • Contact us
    • Work with us
      • Working at DNDi
      • Job opportunities
      • Requests for proposal
  • Donate
Home > Viewpoints

The Role of Neglected Disease-Endemic, Emerging-Economy Countries in Neglected Disease R&D: Latin America on the Rise

11 Sep 2013

Eric StobbaertsViewpoint by

Eric Stobbaerts, Head of DNDi Latin America

As DNDi marks its 10 years of existence, the time is ripe to assess the achievements and difficulties experienced in order to move into a new decade with new approaches. For Latin America, in particular, this period is unique, even transformative, as it is marked by unprecedented economic and social strengthening of the region. This growth brings with it the crucial role of Latin America’s public and private sectors in contributing meaningfully to the neglected disease research and development landscape. The activities of DNDi Latin America are focused on contributing to this process and have expanded with increasing opportunities to partner with ministries of health and national control programmes, but also other non-governmental and private-sector actors, to address the needs of patients suffering from neglected tropical diseases endemic in the region.

An example of this is the recently hosted ‘Chagas Week’ in Argentina, at which DNDi entered into an operational relationship with the Mundo Sano Foundation and the pharmaceutical company ELEA, while strengthening ties with the Argentinian Ministry of Science, and other stakeholders. In Mexico, the Carlos Slim Health Award we received this year has allowed DNDi to build greater presence in this country by identifying new partners and advocating for patient access to Chagas treatment. Colombia is also now part of our operations as we gear up for a clinical study on a cutaneous leishmaniasis treatment.

In Brazil, there is an unprecedented bourgeoning of activity that will certainly expand to neighbouring countries. This year, for instance, for the first time at DNDi, a discovery programme is being set up by a regional office in an endemic country. This programme – LOLA, Lead Optimization in Latin America – was inaugurated with a partnership agreement with the University of Campinas (Unicamp) in Sao Paulo, Brazil, to seek optimization of new molecules against Trypanosona cruzi and Leishmania spp for the treatment of Chagas disease and leishmaniasis. A collaboration agreement with the University of Sao Paulo- Sao Carlos is also eminent. As this programme develops, we are optimistic that other regional and international partners will follow suite.

LOLA is one of the many R&D projects currently taking place in the region. In 10 years, the clinical pipeline of projects has substantially grown, for example for Chagas disease, with the Phase II clinical study of E1224 to evaluate safety and efficacy for the treatment of adult patients with chronic indeterminate Chagas disease, and a study on biomarkers as clear and early markers to indicate parasitological treatment outcome and later indicate definite cure.

The scenario for leishmaniasis is similar. The VL study in Brazil, supported by the Brazilian Ministry of Health to assess current treatments for the diseases, is progressing with five active sites and the 2013 milestone of completing the recruitment of 50% of the trial patients was achieved in May. The revised VL treatment guidelines in Brazil, to be released by October, will likely contain changes based on evidence provided by the study.

Two of the six treatments delivered by DNDi overall were developed in the Latin American region: ASMQ for malaria and the paediatric dosage form of benznidazole for Chagas disease – two successes, yet with many barriers to overcome in order to ensure patient access to the treatments. Our advocacy activities are heavily focused on the need for treatment now, and our R&D work on ensuring better, game-changing treatments in the longer term.

As part of the international Chagas Coalition – including DNDi, Carlos Slim Health Institute, Sabin Vaccine Institute, Mundo Sano Foundation, ISGlobal, Ceades, and with support by Doctors Without Borders and FINDECHAGAS patient federation – we aim to boost access to diagnosis and treatment for Chagas patients and accelerate efforts to stimulate innovation for new health tools to fight the disease. The Coalition has taken on the ‘Time to Treat’ mission to ensure further action.

Finally, following the resolution adopted at the World Health Assembly (WHA) last May, a very exciting state-driven, endemic country-led effort to deliver innovation for the health needs of developing countries has engendered discussions on proposals for ‘demonstration projects’ that incorporate the key principles of the resolution. DNDi Latin America and the MSF Access Campaign are partnering to contribute to the architecture of such projects, the concept of which is new to the region.

In short, the region of Latin America holds the potential to play a unique and major role in neglected disease research and development. There are, however, challenges to overcome. We have seen, over a decade, that when neglected-disease endemic countries become emerging economies with clearer agendas to defeat poverty within their borders, there is an incredible window of opportunity to stimulate patient needs-driven innovation. As a regionally embedded organization, we have to catalyse and support this unprecedented moment for Latin America by bringing together the conduct of research, engagement of governments, leveraging of private sector capacities, fundraising opportunities, and civil society engagement, all in support of one key goal: treating the most neglected patients of the region, and beyond.

Eric Stobbaerts
Head of DNDi Latin America

Read, watch, share

Loading...
News
6 Jun 2025

DNDi is partnering with Médecins Sans Frontières South Asia for the Without Borders Media Fellowship 2025 

News
5 Jun 2025

Meet the DNDi Eastern Africa 2024-2025 Media Fellows

Press releases
5 Jun 2025

Colombia becomes first country to recommend rapid tests to diagnose Chagas disease

Statements
27 May 2025

DNDi interventions at the 78th World Health Assembly

Press releases
22 May 2025

Six African nations commit to eliminate deadly neglected disease visceral leishmaniasis

Videos
20 May 2025

The Children of the Sierra

Press releases
13 May 2025

First all-oral treatment for a rare but deadly strain of sleeping sickness now available and being used to treat patients in endemic countries in Africa

Statements
8 May 2025

DNDi’s briefing note for 78th World Health Assembly

VIEW ALL

Help neglected patients

To date, we have delivered thirteen new treatments, saving millions of lives.

Our goal is to deliver 25 new treatments in our first 25 years. You can help us get there. 

GIVE NOW
Linkedin-in Instagram Twitter Facebook-f Youtube
International non-profit developing safe, effective, and affordable treatments for the most neglected patients.

Learn more

  • Diseases
  • Neglected tropical diseases
  • R&D portfolio
  • Policy advocacy

Get in touch

  • Our offices
  • Contact us
  • Integrity Line

Support us

  • Donate
  • Subscribe to eNews

Work with us

  • Join research networks
  • Jobs
  • RFPs
  • Terms of Use   
  •   Acceptable Use Policy   
  •   Privacy Policy   
  •   Cookie Policy   
  •   Our policies   

  • Except for images, films and trademarks which are subject to DNDi’s Terms of Use, content on this site is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Switzerland License